Interleukin Gets Delisting Notice from NYSE AMEX | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic-test maker Interleukin Genetics said after the close of the market Friday that it has received a delisting notice from the New York Stock Exchange's American Stock Exchange.

The firm said that the exchange has initiated delist proceedings because it has not regained compliance with certain regulations — it has stockholders' equity of less than $6 million and losses from continuing operations and/or net losses in its five most recent fiscal years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.